BioStock has interviewed CSO Jan Stenvang about a new publication on irinotecan predictive biomarkers in colon cancer patients. In collaboration with academica collaborators we have published a new study demonstrating that biomarkes can identify colon cancer patients that are resistant to irinotecan, which is the patients that would be predicted to benefit the most from SCO-101treatment.
The publication can be read here: Predictive biomarkers for irinotecan in colon cancer patients
The BioStock interview can be read here: https://www.biostock.se/2020/04/ny-studie-oppnar-dorren-till-precisionsmedicin-for-scandion-oncology/